Outcome of the Board Meeting of Cian Healthcare Limited held on May 30, 2026- Audited Financial Results (Standalone and Consolidated) for the half-year and Financial Year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cian Healthcare Limited reported audited financial results for FY 2025-26 with a net loss of Rs. 1,499.51 lakhs. The company is in a restart phase following completion of Corporate Insolvency Resolution Process (CIRP) - the NCLT approved a Resolution Plan on December 18, 2025, and new management took over on February 1, 2026. The company is now a subsidiary of Ananta Medicare Limited with fresh equity capital of Rs. 25 crores. Revenue for the half-year stood at Rs. 106.61 lakhs as operations are being rebuilt. The auditors issued a Qualified Opinion citing multiple issues: unconfirmed trade receivables, advances and deposits; unverifiable PPE and inventory values; inventory revaluation loss of Rs. 1,353.73 lakhs; Rs. 347.28 lakhs GST write-off; and inadequate internal financial controls. Exceptional items include large write-offs totaling several crores for deferred expenditure, CWIP, doubtful assets, and investment in subsidiary Dr. Smith's Biotech (which is also under CIRP).
The qualified audit opinion with multiple material uncertainties raises significant concerns about financial statement reliability. The company is rebuilding post-insolvency but faces challenges with unverifiable asset values and weak internal controls. The Rs. 1,499.51 lakh loss and negative operating cash flows indicate ongoing financial stress despite the resolution plan implementation.